MLIC
MRKR icon

Mandatum Life Insurance Company’s Marker Therapeutics MRKR Stock Holding History

Mandatum Life Insurance Company’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9,900
Closed -$26K – 70
2022
Q4 		$26K Hold
9,900
– – 0.01% 66
2022
Q3 		$37K Hold
9,900
– – 0.01% 66
2022
Q2 		$33K Hold
9,900
– – 0.01% 74
2022
Q1 		$44K Hold
9,900
– – 0.01% 79
2021
Q4 		$94K Hold
9,900
– – 0.02% 79
2021
Q3 		$167K Buy
+9,900
New +$203K 0.03% 106

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mandatum Life Insurance Company's MRKR Position: Q1 2023 in Review

Mandatum Life Insurance Company sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 9,900 shares — an estimated $26K sold.

Mandatum Life Insurance Company first reported a position in MRKR in Q3 2021 and held it in 6 quarters. The position peaked at $167K in Q3 2021. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

  • Mandatum Life Insurance Company reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mandatum Life Insurance Company sold 9,900 Marker Therapeutics shares in Q1 2023, an estimated $26K.
  • Mandatum Life Insurance Company first reported a position in Marker Therapeutics in Q3 2021 and held it in 6 quarters.
  • Mandatum Life Insurance Company's Marker Therapeutics position peaked at $167K in Q3 2021.
  • 30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Mandatum Life Insurance Company's 13F filing for Q1 2023, filed 9 May 2023.